Subscribe Become an Author Log In

BiopharmaTrend.com

Covering emerging technologies, innovations, and companies

Big Data


Introducing Sysrev: The Intelligent Platform For Document Review And Automated Data Extraction

   by Thomas Luechtefeld    260
Introducing Sysrev: The Intelligent Platform For Document Review And Automated Data Extraction

In today’s technological world, data is perhaps the single most important driver of a business’ success. Access to relevant data allows businesses to make a variety of informed decisions. Unfortunately, acquiring this data can be quite cumbersome as employees spend countless hours manually reviewing documents. This is especially true for more complex reviews such as journal publications, patient records, or technical specifications. Sysrev offers enterprise a platform for managing collaborative document reviews, injecting machine learning into the review process to increase accuracy and efficiency. Depending on the data source and task, Sysrev can even automate data extraction.

Sysrev, launched in June 2019, is an intelligent platform for document reviews and automated data extraction. Sysrev optimizes the review process with machine learning and adds efficiency through its intuitive, and collaborative, interface.

Chemchart Enterprise: an Intelligent Platform for Chemical Data Management

   by TJ Bozada    361
Chemchart Enterprise: an Intelligent Platform for Chemical Data Management

Chemical data management is an important process to a number of industries, especially those engaged in manufacturing or research and development.  Unfortunately, chemical data is as unwieldy to manage as it is important.  This is for a variety of reasons, but the biggest contributing factor is the sheer amount of data available to the public and managed by an enterprise.  For decades, chemical data has been recorded in paper, and then excel sheets, and now databases.  While efforts have been made to homogenize, or at least centralize this data, there is not one single solution for indexing and searching the wide variety of data types, and sources, managed by an individual enterprise.  Chemchart Enterprise changes this paradigm by combining the flexibility of big data with the precision of machine learning, providing a single solution for managing the entire organization chemical space.

Confluence of Technologies Can Bring “Virtual Pharmacology” to the Next Level

   by Andrii Buvailo    1482
Confluence of Technologies Can Bring “Virtual Pharmacology” to the Next Level

In 1970-80s, the idea of virtual screening was regarded as a conceptual way to substitute costly and time-consuming experimental “screen-everything-you-have” approaches with a much faster and cheaper predictive modelling to cherry-pick only the best molecules for subsequent synthesis and validation in a lab. A great number of computational tools and approaches emerged, aiming at “pre-screening” new promising molecules, so called “hits”, or augmenting experimental screening programs to optimize efforts.

2018: AI Is Surging In Drug Discovery Market

   by Andrii Buvailo    12964
2018: AI Is Surging In Drug Discovery Market

Updated: 10.01.2019. Newly added content is marked in the text with "Update" sign.

The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a surge of activity in this area over the last several years. In 2018, things are getting even “hotter” with the increase in the amount of partnerships, investments and other important events, summarized and grouped below into “mini-trends”.

Democratizing Artificial Intelligence For Pharmaceutical Research

   by Andrii Buvailo    1319
Democratizing Artificial Intelligence For Pharmaceutical Research

Over the last five years the interest of pharmaceutical professionals towards machine learning (ML) and artificial intelligence (AI) has measurably increased -- while only one “AI-related” research collaboration involving “big pharma” appeared in the news in 2013, the number of such events increased up to 21 in 2017 alone, involving some of the top pharma players like GSK, Sanofi, Abbvie, Genentech, etc.